Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry
Zhang, Junfen; Boesjes, Celeste M; Loman, Laura; Kamphuis, Esmé; Romeijn, Margreet L E; Spekhorst, Lotte S; Haeck, Inge; van der Gang, Lian F; Dekkers, Coco C; van der Rijst, Lisa P; Oosting, Albert J; van Lumig, Paula; van Lynden-van Nes, Anneke M T; Tupker, Ron A; Nijssen, Annieke; Flinterman, Annebeth; Politiek, Klaziena; Touwslager, Wouter R H; Christoffers, Wianda A; Stewart, Shiarra M; Kamsteeg, Marijke; de Graaf, Marlies; de Bruin-Weller, Marjolein S; Schuttelaar, Marie-Louise A
(2024) Journal of the American Academy of Dermatology, volume 91, issue 2, pp. 300 - 311
(Article)
Abstract
Background: Long-term daily practice data on patient-reported benefits of dupilumab for atopic dermatitis (AD) remains limited. Objective: To evaluate patient-reported outcome measures (PROMs) and the safety of dupilumab in patients with moderate-to-severe AD over a follow-up period of up to 5 years. Methods: Data were extracted from the prospective, multicenter
... read more
BioDay registry (October 2017–2022) of patients with moderate-to-severe AD treated with dupilumab in daily practice. Results: In total 1223 patients, 1108 adults and 115 pediatric patients were included. After ≥1 year of treatment, mean Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Numeric rating scale (NRS)-pruritus ranged between 7.8 and 8.7, 3.5 and 4.2, and 2.9 and 3.1 in adults, respectively, whilst these patient-reported outcome measures (PROMs) ranged between 8.9 and 10.9, 4.4 and 6.4, and 3.0 and 3.7 in pediatric patients, respectively. At follow-up, overall work impairment decreased from 40.1% to 16.3% to 13.3% in adults. Furthermore, class I obesity and itch-dominant patients generally had less favorable treatment response. Of all patients, 66.8% reported ≥1 adverse event, with conjunctivitis being the most common (33.7%). Limitations: The overall percentage of missing values for selected PROMs was 26% in adults and 46% in pediatric patients. Conclusion: In addition to favorable safety, dupilumab has demonstrated sustained effectiveness across various PROMs, underscoring the treatment benefits from patients' perspectives.
show less
Download/Full Text
Keywords: atopic dermatitis, atopic eczema, daily practice, dupilumab, effectiveness, patient-reported outcomes, safety, Dermatology, Journal Article
ISSN: 0190-9622
Publisher: Mosby Inc.
Note: Publisher Copyright: © 2024 American Academy of Dermatology, Inc.
(Peer reviewed)